Homozygosity for a CHEK2*1100delC mutation identified in familial colorectal cancer does not lead to a severe clinical phenotype

Journal of Pathology

Volumn 206, Issue 2, 2005, Pages 198-204

  van Puijenbroek, Marjo ^a   van Asperen, Christi J ^a   van Mil, Anneke ^a   Devilee, Peter ^a   van Wezel, Tom ^a   Morreau, Hans ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CHEK2; Familial colorectal cancer; HNPCC; TMA

Indexed keywords

CHECKPOINT KINASE 2; ENZYME ANTIBODY; ENZYME VARIANT; PROTEIN SERINE THREONINE KINASE; TUMOR PROTEIN;

ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE SEVERITY; FAMILIAL CANCER; GENE DELETION; GERM LINE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; TISSUE MICROARRAY; AGED; COLORECTAL TUMOR; DNA MICROARRAY; FEMALE; GENETIC PREDISPOSITION; GENETICS; HOMOZYGOTE; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PEDIGREE; POLYMERASE CHAIN REACTION;

AGED; BASE SEQUENCE; COLORECTAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; NEOPLASTIC SYNDROMES, HEREDITARY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEDIGREE; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTEIN-SERINE-THREONINE KINASES;

EID: 19944391947     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1764     Document Type: Article

References (31)

1. Li J, Williams BL, Haire LF, et al. Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2. Mol Cell 2002; 9: 1045-1054.
2. Sodha N, Houlston RS, Williams R, Yuille MA, Mangion J, Eeles RA. A robust method for detecting CHK2/RAD53 mutations in genomic DNA. Hum Mutat 2002; 19: 173-177.
3. Sodha N, Williams R, Mangion J, Bullock SL, Yuille MR, Eeles RA. Screening hCHK2 for mutations. Science 2000; 289: 359.
4. Lee SB, Kim SH, Bell DW, et al. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni syndrome. Cancer Res 2001; 61: 8062-8067.
5. Wu X, Webster SR, Chen J. Characterization of tumor-associated Chk2 mutations. J Biol Chem 2001; 276: 2971-2974.
6. Meijers-Heijboer H, Van Den OA, Klijn J, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nature Genet 2002; 31: 55-59.
7. Vahteristo P, Bartkova J, Eerola H, et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002; 71: 432-438.
8. Kilpivaara O, Vahteristo P, Falck J, et al. CHEK2 variant I157T may be associated with increased breast cancer risk. Int J Cancer 2004; 111: 543-547.
9. Oldenburg RA, Kroeze-Jansema K, Kraan J, et al. The CHEK2* 1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Res 2003; 63: 8153-8157.
10. Meijers-Heijboer H, Wijnen J, Vasen H, et al. The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet 2003; 72: 1308-1314.
11. The CHEK2 Breast Cancer Case-Control Consortium. CHEK2* 1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 2004; 74: 1175-1182.
12. Kilpivaara O, Laiho P, Aaltonen LA, Nevanlinna H. CHEK2 1100delC and colorectal cancer. J Med Genet 2003; 40: e110.
13. Cybulski C, Gorski B, Huzarski T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004; 75: 1131-1135.
14. Sodha N, Bullock S, Taylor R, et al. CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours. Br J Cancer 2002; 87: 1445-1448.
15. Bell DW, Varley JM, Szydlo TE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999; 286: 2528-2531.
16. Dong X, Wang L, Taniguchi K, et al. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 2003; 72: 270-280.
17. Seppala EH, Ikonen T, Mononen N, et al. CHEK2 variants associate with hereditary prostate cancer. Br J Cancer 2003; 89: 1966-1970.
18. Sodha N, Houlston RS, Bullock S, et al. Increasing evidence that germline mutations in CHEK2 do not cause Li-Fraumeni syndrome. Hum Mutat 2002; 20: 460-462.
19. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Med 1998; 4: 844-847.
20. Lukas C, Bartkova J, Latella L, et al. DNA damage-activated kinase Chk2 is independent of proliferation or differentiation yet correlates with tissue biology. Cancer Res 2001; 61: 4990-4993.
21. De Jong AE, van Puijenbroek M, Hendriks Y, et al. Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004; 10: 972-980.
22. Cleton-Jansen AM, Timmerman MC, van de Vijver MJ, et al. A distinct phenotype characterizes tumors from a putative genetic trait involving chondrosarcoma and breast cancer occurring in the same patient. Lab Invest 2004; 84: 191-202.
23. Wang L, Baudhuin LM, Boardman LA, et al. MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps. Gastroenterology 2004; 127: 9-16.
24. Jones S, Lambert S, Williams GT, et al. Increased frequency of the k-ras G12C mutation in MYH polyposis colorectal adenomas. Br J Cancer 2004; 90: 1591-1593.
25. Zhou BB, Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nature Rev Cancer 2004; 4: 216-225.
26. Hirao A, Cheung A, Duncan G, et al. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol 2002; 22: 6521-6532.
27. Jallepalli PV, Lengauer C, Vogelstein B, Bunz F. The Chk2 tumor suppressor is not required for p53 responses in human cancer cells. J Biol Chem 2003; 278: 20 475-20 479.
28. Broeks A, de Witte L, Nooijen A, et al. Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers. Breast Cancer Res Treat 2004; 83: 91-93.
29. Kilpivaara O, Bartkova J, Eerola H, et al. Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer 2005; 113: 575-580.
30. Lipton L, Fleischmann C, Sieber OM, et al. Contribution of the CHEK2 1100delC variant to risk of multiple colorectal adenoma and carcinoma. Cancer Lett 2003; 200: 149-152.
31. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-5257.